Nurix reports 83% response rate for bexobrutideg in CLL patients

Nurix reported strong Phase 1a/1b data for oral BTK degrader bexobrutideg in relapsed/refractory B‑cell malignancies, with an 83% objective response rate in CLL and a median progression‑free survival of 22.1 months across 47 evaluable Phase 1a patients; two complete responses were observed and the population was heavily pretreated (median three prior therapies). Randomized Phase 1b data showed higher response at the 600 mg daily dose (83.3% vs 73.7%), prompting selection of 600 mg as the recommended Phase 2 dose and initiation/enrollment of the pivotal DAYBreak CLL‑201 trial; the company also completed a $250 million equity offering to fund development. Additional translational data for NX‑1607 and a board appointment (Roger Dansey, M.D.) were disclosed, while H.C. Wainwright cut its price target to $28 but maintained a Buy rating; Nurix’s market cap is reported at $1.83 billion and shares have risen ~41% over the past six months.

Analysis

Market structure: Nurix (NRIX) is the clear near-term beneficiary — a successful BTK degrader that works in BTKi-resistant CLL can reallocate share from incumbent BTK inhibitor franchises (long-term pressure on players like ABBV/JNJ) and lift suppliers/CROs. The $250m equity raise increases float and will cap a near-term supply-driven pop; expect elevated implied volatility and heavy options flow for 30–90 days as traders trade data cadence and dilution risk. Cross-asset effects will be modest: tighter small-cap biotech credit spreads and higher biotech ETF (XBI) vol, muted FX/commodity impact.

Risk assessment: Key tail risks are a negative Phase 2 or safety signal (bleeding, neutropenia) that could erase >50% of market value, regulatory rejection on durability, or follow-on dilution >20–30% if cash runway shortens. Time horizons: immediate (days) — post-ASH momentum and IV spikes; short (weeks–months) — DAYBreak enrollment, interim signals, analyst PT revisions; long (12–36 months) — pivotal readout, approval, commercial uptake and potential M&A. Hidden dependencies include durability (PFS >18–24 months needed for durable commercial case), payer willingness, and potential competition from pharma fast-followers.

Trade implications: Tactical long exposure to NRIX warranted but sized and protected: size 2–3% portfolio via stock or defined-cost LEAP call spreads to capture a positive Phase 2 without unlimited downside; take profits on +40–60% or convert to covered calls. Relative play: long NRIX / short XBI (equal dollar notional) to isolate company-specific upside vs sector moves. Options: prefer debit call spreads (12–18 month expiries) to limit premium loss; avoid naked short volatility in NRIX until post-Phase 2 volatility normalizes.

Contrarian angles: Consensus overlooks dilution and immature durability data — 83% ORR in Phase 1a is promising but not definitive; assume material drop-off in response durability until DAYBreak interim confirms PFS. The market may be over-rewarding mechanism novelty; if NRIX market cap reaches >$3bn without Phase 2 readout or clear commercial partner in 12 months, expect mean reversion or risk-premium compression via secondary offerings. Conversely, successful Phase 2 + partner could trigger 50–100% upside or acquisition arbitrage.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in NRIX via a defined-cost structure within 2–8 weeks: buy NRIX stock or implement a 12–18 month call spread (e.g., Jan 2027 $20–$40 debit spread) to limit downside; set stop-loss to reduce to 0.5% position if NRIX drops 25% from entry.
• For lower cash outlay, buy a Jan 2027 NRIX LEAP call and simultaneously sell a higher strike (vertical) to finance ~50–70% of premium (target net debit < $4–6/share equivalent); plan to exit or roll on a positive Phase 2 interim or if premium decays >60%.
• Execute a pair trade: go long NRIX (1x) and short XBI (0.75–1x) equal-dollar to neutralize sector beta; reduce short leg if XBI outperforms by >10% in 30 days or close pair if NRIX rises >50%.
• Do not increase position above 5% prior to DAYBreak interim readout (expected within 6–12 months). Monitor three concrete triggers in the next 90 days: (1) DAYBreak enrollment rate and protocol amendments, (2) any new safety signals reported to FDA/SEC, and (3) further equity raises >$150m — if any occur, cut position by at least 50%.